Literature DB >> 19732723

The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.

Lars Klemm1, Cihangir Duy, Ilaria Iacobucci, Stefan Kuchen, Gregor von Levetzow, Niklas Feldhahn, Nadine Henke, Zhiyu Li, Thomas K Hoffmann, Yong-mi Kim, Wolf-Karsten Hofmann, Hassan Jumaa, John Groffen, Nora Heisterkamp, Giovanni Martinelli, Michael R Lieber, Rafael Casellas, Markus Müschen.   

Abstract

Chronic myeloid leukemia (CML) is induced by BCR-ABL1 and can be effectively treated for many years with Imatinib until leukemia cells acquire drug resistance through BCR-ABL1 mutations and progress into fatal B lymphoid blast crisis (LBC). Despite its clinical significance, the mechanism of progression into LBC is unknown. Here, we show that LBC but not CML cells express the B cell-specific mutator enzyme AID. We demonstrate that AID expression in CML cells promotes overall genetic instability by hypermutation of tumor suppressor and DNA repair genes. Importantly, our data uncover a causative role of AID activity in the acquisition of BCR-ABL1 mutations leading to Imatinib resistance, thus providing a rationale for the rapid development of drug resistance and blast crisis progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732723      PMCID: PMC2931825          DOI: 10.1016/j.ccr.2009.07.030

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  54 in total

1.  AID is required for germinal center-derived lymphomagenesis.

Authors:  Laura Pasqualucci; Govind Bhagat; Mila Jankovic; Mara Compagno; Paula Smith; Masamichi Muramatsu; Tasuku Honjo; Herbert C Morse; Michel C Nussenzweig; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

2.  Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:  Heike Pfeifer; Barbara Wassmann; Anna Pavlova; Lydia Wunderle; Johannes Oldenburg; Anja Binckebanck; Thoralf Lange; Andreas Hochhaus; Silvia Wystub; Patrick Brück; Dieter Hoelzer; Oliver G Ottmann
Journal:  Blood       Date:  2007-04-03       Impact factor: 22.113

3.  Strand-biased spreading of mutations during somatic hypermutation.

Authors:  Shyam Unniraman; David G Schatz
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

4.  Regulation of AID expression in the immune response.

Authors:  Elizabeth E Crouch; Zhiyu Li; Makiko Takizawa; Stefan Fichtner-Feigl; Polyxeni Gourzi; Carolina Montaño; Lionel Feigenbaum; Patrick Wilson; Siegfried Janz; F Nina Papavasiliou; Rafael Casellas
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

5.  Brca1 in immunoglobulin gene conversion and somatic hypermutation.

Authors:  Simonne Longerich; Brian J Orelli; Richard W Martin; Douglas K Bishop; Ursula Storb
Journal:  DNA Repair (Amst)       Date:  2007-11-26

Review 6.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

7.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

8.  Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.

Authors:  Georg Lenz; Inga Nagel; Reiner Siebert; Anna V Roschke; Warren Sanger; George W Wright; Sandeep S Dave; Bruce Tan; Hong Zhao; Andreas Rosenwald; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Elias Campo; Elaine S Jaffe; Erlend B Smeland; Richard I Fisher; W Michael Kuehl; Wing C Chan; Louis M Staudt
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

9.  Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-kappaB.

Authors:  Polyxeni Gourzi; Tatyana Leonova; F Nina Papavasiliou
Journal:  J Exp Med       Date:  2007-01-22       Impact factor: 14.307

10.  Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.

Authors:  Niklas Feldhahn; Nadine Henke; Kai Melchior; Cihangir Duy; Bonaventure Ndikung Soh; Florian Klein; Gregor von Levetzow; Bernd Giebel; Aihong Li; Wolf-Karsten Hofmann; Hassan Jumaa; Markus Müschen
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more
  72 in total

Review 1.  The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential.

Authors:  Christopher S Nabel; Sara A Manning; Rahul M Kohli
Journal:  ACS Chem Biol       Date:  2011-10-31       Impact factor: 5.100

Review 2.  Complex regulation and function of activation-induced cytidine deaminase.

Authors:  Janet Stavnezer
Journal:  Trends Immunol       Date:  2011-04-13       Impact factor: 16.687

3.  Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.

Authors:  Tanja Andrea Gruber; Mi Sook Chang; Richard Sposto; Markus Müschen
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

4.  APOBEC3A damages the cellular genome during DNA replication.

Authors:  Abby M Green; Sébastien Landry; Konstantin Budagyan; Daphne C Avgousti; Sophia Shalhout; Ashok S Bhagwat; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia.

Authors:  Daniel W Thomson; Nur Hezrin Shahrin; Paul P S Wang; Carol Wadham; Naranie Shanmuganathan; Hamish S Scott; Marcel E Dinger; Timothy P Hughes; Andreas W Schreiber; Susan Branford
Journal:  Leukemia       Date:  2020-02-19       Impact factor: 11.528

Review 6.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

7.  Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.

Authors:  Yan-jun Zhang; Cheng-rong Lu; Yan Cao; Yuan Luo; Rong-feng Bao; Shu Yan; Mei Xue; Feng Zhu; Zhe Wang; Lian-ning Duan
Journal:  Acta Pharmacol Sin       Date:  2012-03-05       Impact factor: 6.150

8.  HSP90 inhibitors decrease AID levels and activity in mice and in human cells.

Authors:  Damien Montamat-Sicotte; Ludivine C Litzler; Cecilia Abreu; Shiva Safavi; Astrid Zahn; Alexandre Orthwein; Markus Müschen; Pablo Oppezzo; Denise P Muñoz; Javier M Di Noia
Journal:  Eur J Immunol       Date:  2015-05-18       Impact factor: 5.532

9.  Regulation of activation-induced deaminase stability and antibody gene diversification by Hsp90.

Authors:  Alexandre Orthwein; Anne-Marie Patenaude; El Bachir Affar; Alain Lamarre; Jason C Young; Javier M Di Noia
Journal:  J Exp Med       Date:  2010-11-01       Impact factor: 14.307

Review 10.  AID targeting: old mysteries and new challenges.

Authors:  Vivek Chandra; Alexandra Bortnick; Cornelis Murre
Journal:  Trends Immunol       Date:  2015-08-04       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.